There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alexion Pharmaceuticals (ALXN) and Edwards Lifesciences (EW) with bullish sentiments.
Alexion Pharmaceuticals (ALXN)
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $159.00. The company’s shares closed last Monday at $100.30, close to its 52-week low of $94.59.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 8.0% and a 38.5% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, CymaBay Therapeutics, and ChemoCentryx.
Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $148.92, representing a 40.5% upside. In a report released yesterday, Cowen & Co. also assigned a Buy rating to the stock with a $165.00 price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences (EW)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Edwards Lifesciences today and set a price target of $272.00. The company’s shares closed last Monday at $233.97, close to its 52-week high of $247.64.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 15.7% and a 73.2% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $270.69, representing a 17.5% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $280.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
